{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T04:12:56Z","timestamp":1751343176802,"version":"3.41.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,30]]},"DOI":"10.7759\/cureus.87052","type":"journal-article","created":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T18:57:34Z","timestamp":1751309854000},"source":"Crossref","is-referenced-by-count":0,"title":["The Role of Sulopenem in the Treatment of Uncomplicated Urinary Tract Infections: A Systematic Review and Meta-Analysis"],"prefix":"10.7759","author":[{"given":"Quang D","family":"La","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Han B","family":"La","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francis","family":"Pryor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noor","family":"Rajpoot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noman","family":"Sadiq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens12040623","article-title":"Urinary tract infections: the current scenario and future prospects","volume":"12","author":"Mancuso G","year":"2023","unstructured":"Mancuso G, Midiri A, Gerace E, Marra M, Zummo S, Biondo C. Urinary tract infections: the current scenario and future prospects. Pathogens. 2023, 12:10.3390\/pathogens12040623","journal-title":"Pathogens"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.medmic.2024.100114","article-title":"Bacterial etiology and antimicrobial resistance pattern of community-acquired urinary tract infection in older adults","volume":"22","author":"Taha AB","year":"2024","unstructured":"Taha AB. Bacterial etiology and antimicrobial resistance pattern of community-acquired urinary tract infection in older adults. Med Microecol. 2024, 22:100114. 10.1016\/j.medmic.2024.100114","journal-title":"Med Microecol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms13020422","article-title":"Urinary tract infections caused by Klebsiella pneumoniae and prolonged treatment with trimethoprim\/sulfamethoxazole","volume":"13","author":"Filev R","year":"2025","unstructured":"Filev R, Lyubomirova M, Bogov B, Kolevski A, Pencheva V, Kalinov K, Rostaing L. Urinary tract infections caused by Klebsiella pneumoniae and prolonged treatment with trimethoprim\/sulfamethoxazole. Microorganisms. 2025, 13:10.3390\/microorganisms13020422","journal-title":"Microorganisms"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.annemergmed.2020.08.022","article-title":"Emergence of extended-spectrum \u03b2-lactamase urinary tract infections among hospitalized emergency department patients in the United States","volume":"77","author":"Talan DA","year":"2021","unstructured":"Talan DA, Takhar SS, Krishnadasan A, et al.. Emergence of extended-spectrum \u03b2-lactamase urinary tract infections among hospitalized emergency department patients in the United States. Ann Emerg Med. 2021, 77:32-43. 10.1016\/j.annemergmed.2020.08.022","journal-title":"Ann Emerg Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.01898-24","article-title":"Characterization of sulopenem antimicrobial activity using in vitro time-kill kinetics, synergy, post-antibiotic effect, and sub-inhibitory MIC effect methods against Escherichia coli and Klebsiella pneumoniae isolates","volume":"13","author":"Maher JM","year":"2025","unstructured":"Maher JM, Huband MD, Lindley JM, Rhomberg PR, Aronin SI, Puttagunta S, Castanheira M. Characterization of sulopenem antimicrobial activity using in vitro time-kill kinetics, synergy, post-antibiotic effect, and sub-inhibitory MIC effect methods against Escherichia coli and Klebsiella pneumoniae isolates. Microbiol Spectr. 2025, 13:e0189824. 10.1128\/spectrum.01898-24","journal-title":"Microbiol Spectr"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-022-01688-1","article-title":"Sulopenem: an intravenous and oral penem for the treatment of urinary tract infections due to multidrug-resistant bacteria","volume":"82","author":"Zhanel GG","year":"2022","unstructured":"Zhanel GG, Pozdirca M, Golden AR, et al.. Sulopenem: an intravenous and oral penem for the treatment of urinary tract infections due to multidrug-resistant bacteria. Drugs. 2022, 82:533-57. 10.1007\/s40265-022-01688-1","journal-title":"Drugs"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac738","article-title":"Sulopenem or ciprofloxacin for the treatment of uncomplicated urinary tract infections in women: a phase 3, randomized trial","volume":"76","author":"Dunne MW","year":"2023","unstructured":"Dunne MW, Aronin SI, Das AF, Akinapelli K, Zelasky MT, Puttagunta S, Boucher HW. Sulopenem or ciprofloxacin for the treatment of uncomplicated urinary tract infections in women: a phase 3, randomized trial. Clin Infect Dis. 2023, 76:66-77. 10.1093\/cid\/ciac738","journal-title":"Clin Infect Dis"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3390\/healthcare11131946","article-title":"Antimicrobial resistance: a growing serious threat for global public health","volume":"11","author":"Salam MA","year":"2023","unstructured":"Salam MA, Al-Amin MY, Salam MT, Pawar JS, Akhter N, Rabaan AA, Alqumber MA. Antimicrobial resistance: a growing serious threat for global public health. Healthcare (Basel). 2023, 11:10.3390\/healthcare11131946","journal-title":"Healthcare (Basel)"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1128\/mbio.00609-24","article-title":"Synergistic effects of sulopenem in combination with cefuroxime or durlobactam against Mycobacterium abscessus","volume":"15","author":"Dousa KM","year":"2024","unstructured":"Dousa KM, Shin E, Kurz SG, et al.. Synergistic effects of sulopenem in combination with cefuroxime or durlobactam against Mycobacterium abscessus. mBio. 2024, 15:e0060924. 10.1128\/mbio.00609-24","journal-title":"mBio"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa515.1898","article-title":"Lb-1. Efficacy and safety of oral sulopenem etzadroxil\/probenecid versus oral ciprofloxacin in the treatment of uncomplicated urinary tract infections (uUTI) in adult women: results from the SURE-1 trial","volume":"7","author":"Dunne MW","year":"2020","unstructured":"Dunne MW, Das AF, Zelasky M, Akinapelli K, Boucher H, Aronin SI. Lb-1. Efficacy and safety of oral sulopenem etzadroxil\/probenecid versus oral ciprofloxacin in the treatment of uncomplicated urinary tract infections (uUTI) in adult women: results from the SURE-1 trial. Open Forum Infect Dis. 2020, 7:S844. 10.1093\/ofid\/ofaa515.1898","journal-title":"Open Forum Infect Dis"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab466.1625","article-title":"1433. Impact of 2019 US Food and Drug Administration (FDA) guidance on developing drugs for urinary tract infection (UTI) on the perceived efficacy of antibiotics for the treatment of uncomplicated UTI (uUTI)","volume":"8","author":"Henriksen AS","year":"2021","unstructured":"Henriksen AS, Nicolle L, Das AF. 1433. Impact of 2019 US Food and Drug Administration (FDA) guidance on developing drugs for urinary tract infection (UTI) on the perceived efficacy of antibiotics for the treatment of uncomplicated UTI (uUTI). Open Forum Infect Dis. 2021, 8:S798. 10.1093\/ofid\/ofab466.1625","journal-title":"Open Forum Infect Dis"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofad500.2185","article-title":"2568. Characterization of sulopenem pharmacokinetics-pharmacodynamics using a one-compartment in vitro infection model","volume":"10","author":"VanScoy BD","year":"2023","unstructured":"VanScoy BD, Jones S, Conde H, et al.. 2568. Characterization of sulopenem pharmacokinetics-pharmacodynamics using a one-compartment in vitro infection model. Open Forum Infect Dis. 2023, 10:ofad500.2185. 10.1093\/ofid\/ofad500.2185","journal-title":"Open Forum Infect Dis"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofad500.2186","article-title":"2569. Pharmacokinetic-pharmacodynamic evaluation of sulopenem using a five-day hollow-fiber in vitro infection model","volume":"10","author":"VanScoy BD","year":"2023","unstructured":"VanScoy BD, Conde H, Vincent CE, Bhavnani SM, Aronin SI, Puttagunta S, Ambrose PG. 2569. Pharmacokinetic-pharmacodynamic evaluation of sulopenem using a five-day hollow-fiber in vitro infection model. Open Forum Infect Dis. 2023, 10:ofad500.2186. 10.1093\/ofid\/ofad500.2186","journal-title":"Open Forum Infect Dis"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofae631.1295","article-title":"P-1107. Oral sulopenem\/probenecid for uncomplicated urinary tract infections (uUTI): results from the REASSURE trial","volume":"12","author":"Puttagunta S","year":"2025","unstructured":"Puttagunta S, Aronin SI, Gupta J, Das AF, Gupta K, Dunne MW. P-1107. Oral sulopenem\/probenecid for uncomplicated urinary tract infections (uUTI): results from the REASSURE trial. Open Forum Infect Dis. 2025, 12:ofae631.1295. 10.1093\/ofid\/ofae631.1295","journal-title":"Open Forum Infect Dis"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.1411","article-title":"Risk-of-bias VISualization (robvis): an R package and Shiny web app for visualizing risk-of-bias assessments","volume":"12","author":"McGuinness LA","year":"2021","unstructured":"McGuinness LA, Higgins JP. Risk-of-bias VISualization (robvis): an R package and Shiny web app for visualizing risk-of-bias assessments. Res Synth Methods. 2021, 12:55-61. 10.1002\/jrsm.1411","journal-title":"Res Synth Methods"},{"key":"ref17","unstructured":"GRADE handbook for grading quality of evidence and strength of recommendations. (2013). http.\/\/guidelinedevelopment.org\/handbook."},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics12050870","article-title":"Beta-lactam dose optimisation in the intensive care unit: targets, therapeutic drug monitoring and toxicity","volume":"12","author":"Legg A","year":"2023","unstructured":"Legg A, Carmichael S, Chai MG, Roberts JA, Cotta MO. Beta-lactam dose optimisation in the intensive care unit: targets, therapeutic drug monitoring and toxicity. Antibiotics (Basel). 2023, 12:10.3390\/antibiotics12050870","journal-title":"Antibiotics (Basel)"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13695","article-title":"Complex in vitro model: a transformative model in drug development and precision medicine","volume":"17","author":"Wang L","year":"2023","unstructured":"Wang L, Hu D, Xu J, Hu J, Wang Y. Complex in vitro model: a transformative model in drug development and precision medicine. Clin Transl Sci. 2023, 17:10.1111\/cts.13695","journal-title":"Clin Transl Sci"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1002\/jhm.881","article-title":"Antimicrobial stewardship for inpatient facilities","volume":"6 Suppl 1","author":"Ohl CA","year":"2011","unstructured":"Ohl CA, Luther VP. Antimicrobial stewardship for inpatient facilities. J Hosp Med. 2011, 6 Suppl 1:S4-15. 10.1002\/jhm.881","journal-title":"J Hosp Med"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2023.1212583","article-title":"Considering patient perspectives in economic evaluations of health interventions","volume":"11","author":"Fu R","year":"2023","unstructured":"Fu R, Ng V, Liu M, Wells D, Yurga E, Nauenberg E. Considering patient perspectives in economic evaluations of health interventions. Front Public Health. 2023, 11:1212583. 10.3389\/fpubh.2023.1212583","journal-title":"Front Public Health"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1021\/jm100112j","article-title":"A medicinal chemist's guide to molecular interactions","volume":"53","author":"Bissantz C","year":"2010","unstructured":"Bissantz C, Kuhn B, Stahl M. A medicinal chemist's guide to molecular interactions. J Med Chem. 2010, 53:5061-84. 10.1021\/jm100112j","journal-title":"J Med Chem"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/372159-the-role-of-sulopenem-in-the-treatment-of-uncomplicated-urinary-tract-infections-a-systematic-review-and-meta-analysis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T18:57:35Z","timestamp":1751309855000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/372159-the-role-of-sulopenem-in-the-treatment-of-uncomplicated-urinary-tract-infections-a-systematic-review-and-meta-analysis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,30]]},"references-count":22,"URL":"https:\/\/doi.org\/10.7759\/cureus.87052","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6,30]]}}}